Cognitive Impairment Clinical Trial
— PROMED-EXOfficial title:
A Randomised Controlled Trial to Evaluate the Effect of a Protein Enriched Mediterranean Diet and Exercise Intervention on the Nutritional Status and Cognitive Performance of Adults at Risk of Undernutrition and Cognitive Decline
PROMED-EX is a single-blind, parallel group randomised controlled trial to determine the effect of a PROtein enriched MEDiterranean diet (PROMED) in comparison to a PROtein enriched MEDiterranean diet and EXercise (PROMED-EX) intervention, or standard care on the nutritional status and cognitive performance of older undernourished adults with subjective cognitive decline.
Status | Recruiting |
Enrollment | 105 |
Est. completion date | January 31, 2024 |
Est. primary completion date | January 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility | Inclusion Criteria: - Community-dwelling (non-institutionalised) participants =60 years older - A high risk of undernutrition as defined by a Mini Nutritional Assessment -Short Form (MNA-SF) score of 8 - 11 - Positive screen for Subjective Cognitive Decline (SCD) Exclusion Criteria: - Cognitive impairment determined by the Mini Mental State Assessment (MMSE) or Telephone Cognitive Screen (T-CogS) - Receiving oral or artificial nutritional support or medical food supplements - Taking high dose nutritional supplements (supplements above the Reference Nutrient Intake levels). - Dietary restrictions/allergies that limit ability to adhere to study requirements - A diagnosis of mild cognitive impairment or dementia - Dysphagia - Chronic kidney disease - Poorly controlled diabetes (HbA1c >8% or diabetes complications) - Severe visual or language impairment - Self-reported psychiatric problems or significant medical co-morbidities that compromise the ability to take part/limit capacity to consent - Diagnosis of a comorbid condition that may alter performance on cognitive tests, e.g. stroke, head injury, Parkinson's disease, learning disabilities. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Queen's University Belfast | Belfast | Antrim |
Lead Sponsor | Collaborator |
---|---|
Queen's University, Belfast | Dublin City University, Friedrich-Alexander-Universität Erlangen-Nürnberg, University College Dublin, Wageningen University |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Explore the acceptability and tolerance of the intervention | A study evaluation questionnaire will be administered to participants at 6 months to determine acceptability, tolerance and potential adverse effects of the intervention components and the intervention materials | 6 months | |
Other | Exploratory outcome: Metabolomic profiling | The blood samples required for Metabolomics analysis will be transferred to University College Dublin.
An exploratory outcome using both targeted and untargeted approaches. Metabolomics will be performed using NMR and LC-MS-based approaches. |
Baseline, 3 months and 6 months | |
Primary | Mini Nutritional Assessment Score- Long Form | The Primary outcome is change at 6 months (study endpoint) in Mini Nutritional Assessment (MNA) score between the two intervention groups and the control group. The MNA is a well validated tool with good sensitivity and specificity for predicting nutritional risk in older community dwelling adults. Scores range from 0-30 with a lower score reflecting poorer nutritional status. | Baseline and 6 months | |
Secondary | Mini Nutritional Assessment Score (midpoint change) | Change at 3 months from baseline in Mini Nutritional Assessment (MNA) score between the two intervention groups and the control group. The MNA is a well validated tool with good sensitivity and specificity for predicting nutritional risk in older community dwelling adults. Scores range from 0-30 with a lower score reflecting poorer nutritional status. | Baseline and 3 months | |
Secondary | Nutrient intake: PROMED Mediterranean Diet Score | Change at 3 and 6 months in Mediterranean Diet Score (MDS)(score range 0-14) between the two intervention groups and control. Higher scores reflect greater adherence to a Mediterranean diet. | Baseline, 3 months and 6 months | |
Secondary | Nutrient intake: (4 day food diary) | Change at 3 and 6 months in nutrient intakes (including protein intake) between the two intervention groups and control. | Baseline, 3 months and 6 months | |
Secondary | Simplified Nutrition Appetite Questionnaire (SNAQ) | Change in appetite at 3 and 6 months (from baseline). This is a brief 4-item questionnaire (score range 0-4) with lower scores suggesting deterioration of appetite. | Baseline, 3 months and 6 months | |
Secondary | Body Water (%) | Change in Body water (%) at 3 and 6 months (from baseline) using Bioelectrical Impedance Analysis (BodyStat 1500) | Baseline, 3 months and 6 months | |
Secondary | Total Body Fat (%) | Change in Total Body Fat (%) at 3 and 6 months (from baseline) using Bioelectrical Impedance Analysis (BodyStat 1500) | Baseline, 3 months and 6 months | |
Secondary | Lean Muscle Mass (kg) | Change in Muscle Mass (kg) at 3 and 6 months (from baseline) using Bioelectrical Impedance Analysis (BodyStat 1500) | Baseline, 3 months and 6 months | |
Secondary | Weight (kg) and height (cm) | Change in weight (kg) and Height (cm) at 3 and 6 months (from baseline). Both measurements will be used to calculate change in Body Mass Index (BMI) (Kg/m^2) across groups at 3 and 6 months. | Baseline, 3 months and 6 months | |
Secondary | Waist circumference (cm) | Change in waist circumference at 3 and 6 months (from baseline) | Baseline, 3 months and 6 months | |
Secondary | Physical Activity determined by completion of a Recent Physical Activity Questionnaire | Change at 3 and 6 months (from Baseline) in physical activity levels between the two intervention groups and control. This questionnaire inquires about physical activity across four domains (leisure time, occupation, commuting, and domestic life) during the past 4 weeks. Metabolic Equivalent of Task scores can be calculated and an estimation of total energy expenditure across the four domains. | Baseline, 3 months and 6 months | |
Secondary | Capturing Changes in Cognition (Catch-Cog) | Change at 3 and 6 months (from baseline) in cognition using the Capturing Changes in Cognition- Catch-Cog score. This composite includes an Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) word recognition (Sub score 0-12), ADAS-Cog orientation (Sub score 0-8), Controlled Oral Word Association Test (COWAT) (max number of words in 1 minute), Category Fluency Test (max number of words in 1 minute), a Digital Symbol Substitution test (correct number of symbols matched in 90 seconds), and an ADAS-Cog Word Recall Test (sub score range: 0-10). A higher score reflects better cognitive performance. | Baseline, 3 months and 6 months | |
Secondary | Trail Making Tests (TMT) (Part A & B) | Change in completion time of the TMT at 3 and 6 months (from baseline). Higher time reflects greater impairment. | Baseline, 3 months and 6 months | |
Secondary | Delayed recall test (0-10) | Change at 3 and 6 months (from baseline) in a delayed recall test of recalled learned words after a 5-minute delay (score range 0-10) | Baseline, 3 months and 6 months | |
Secondary | Functional performance measured using the Short Physical Performance Battery (SPPB) test. | Change at 3 and 6 months in functional performance from baseline (using the SBBP): The SPPB will test participant's Gait (time to walk 8 feet), Balance (ability to complete a side-by-side, a semi-tandem and a tandem stand) and Strength (time to complete 5 chair stands). Category scores range from 0-4 and total score (0-12) with a higher score representing better physical functioning. | Baseline, 3 months and 6 months | |
Secondary | Grip Strength measured by isometric grip force (0-100kg) | Change in isometric grip force (0-100kg) at 3 and 6 months (from baseline) using a Dynamometer | Baseline, 3 months and 6 months | |
Secondary | Health-related quality of life (Short Form (SF)-36) | Change in health related quality of life measures at 3 and 6 months between the two intervention groups and control. The SF-36 is a 36-item questionnaire (covering 8 domains of health including physical functioning; role limitations due to physical health; role limitation due to emotional problems; energy/fatigue; emotional well-being; social functioning; pain; general health.Scores range from 0-100 with higher score indicating a better quality of life. | Baseline, 3 months and 6 months | |
Secondary | Geriatric Depression Scale | Change in Depression scale at 3 and 6 months (from baseline) Scores range from 0-15. A score =5 indicates probable depression | Baseline, 3 months and 6 months | |
Secondary | Systolic Blood Pressure (mmHg) | Change at 3 and 6 months (from baseline) using a Omron automated blood pressure monitor | Baseline, 3 months and 6 months | |
Secondary | Diastolic Blood Pressure (mmHg) | Change at 3 and 6 months (from baseline) using an Omron automated blood pressure monitor | Baseline, 3 months and 6 months | |
Secondary | Biochemical markers: nutritional, cardiometabolic and inflammatory | Blood sample will be collected to determine change in serum levels of Vitamin A, Vitamin E , Carotenoids (nmol/l), change in serum lipid profile (Total cholesterol, HDL cholesterol, LDL Cholesterol and triglycerides (mmol/l)), HbA1c (mmol/mol) , fasting plasma glucose (mmol/l) and Insulin (pmol/l), High Sensitivity C-Reactive Protein (mg/l), Interleukin-6 (pg/ml),at 3 and 6 months (from Baseline). | Baseline, 3 months and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Recruiting |
NCT04356924 -
Psychological Treatment to Support the Consequences of Cognitive Impairment
|
N/A | |
Suspended |
NCT05542238 -
The Effect of Acute Exercise on Cardiac Autonomic, Cerebrovascular, and Cognitive Function in Spinal Cord Injury
|
N/A | |
Terminated |
NCT04493957 -
Evaluation of an Educational Program in the Prevention of the Driving Risks in Patients With Neurocognitive Disorders : ACCOMPAGNE
|
N/A | |
Recruiting |
NCT04792983 -
Cognition and the Immunology of Postoperative Outcomes
|
||
Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
Not yet recruiting |
NCT05068323 -
Impact of Interictal Epileptiform Activity on Some Cognitive Domains in Newly Diagnosed Epileptic Patients
|
N/A | |
Completed |
NCT04426838 -
Cognitive Behavioral Therapy for Insomnia for the Dementia Caregiving Dyad
|
N/A | |
Completed |
NCT04713384 -
Remote Bimanual Virtual Rehabilitation Post CVD
|
N/A | |
Recruiting |
NCT06284213 -
Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium
|
||
Recruiting |
NCT06053775 -
Non-Invasive Brain Stimulation and Cognitive Training for Depressive Symptomatology Related to Breast Cancer (ONCODEP)
|
N/A | |
Completed |
NCT03698695 -
A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05552729 -
Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT03187353 -
IMProving Executive Function Study
|
Phase 4 | |
Completed |
NCT03301402 -
Air Purifier to Improve Endothelial Function and Carotid Intima Thickness
|
N/A | |
Completed |
NCT05395559 -
Prevalence and Recognition of Cognitive Impairment in Hospitalized Patients: a Flash Mob Study
|
||
Recruiting |
NCT04907565 -
Impact of Obesity on Post-operative Cognitive Dysfunction: Role of Adipose Tissue
|
||
Recruiting |
NCT05030285 -
Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment
|
N/A | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A |